Glyco-based Vaccine Development Service

Creative Biolabs' glycoprotein-centric vaccine development service is engineered to generate immunogens that preserve native or rationally designed glycosylation profiles. Leveraging mammalian, insect, or yeast expression systems, these glycoproteins are meticulously crafted to replicate pathogen-associated glycan motifs or tumor-specific glycoprotein structures. By harnessing lectin-mediated pathways, the approach enhances immune recognition and uptake by antigen-presenting cells, fostering robust adaptive responses. We offer full-length antigen constructs alongside domain-specific designs, featuring customized N- or O-glycosylation sites to enable precise modulation of antigenicity and immune activation kinetics.

We deliver end-to-end support, from gene synthesis and codon optimization to protein expression, glycoengineering, and rigorous quality validation. The platform accommodates diverse antigen classes—including viral envelope proteins, mucins, and immune checkpoint ligands—with tailored glycan profiling to optimize folding efficiency, epitope accessibility, and biological functionality. This service is ideally suited for infectious disease vaccine pipelines and cancer immunotherapy programs, balancing structural fidelity with enhanced immunogenicity to drive translational success.

Glycopeptide-driven cancer vaccine strategies utilize chemically synthesized or semi-synthetic glycopeptides derived from tumor-associated glycoproteins (e.g., MUC1), adorned with cancer-relevant glycan epitopes such as Tn, STn, or TF antigens. These constructs mimic the aberrant glycosylation signatures characteristic of malignant cells, enabling the disruption of immune tolerance and the induction of dual antibody-mediated and MHC-I-restricted cytotoxic T lymphocyte (CTL) responses—critical mechanisms for tumor surveillance and elimination.

Our service encompasses the entire design-to-validation process, including glycopeptide synthesis, carrier protein conjugation, formulation with immune-modulatory adjuvants (e.g., lipopeptides, TLR agonists), and in vivo efficacy assessment. Creative Biolabs provides strategic expertise in antigen architecture and immunodominant epitope targeting, ensuring vaccine candidates exhibit enhanced cellular immunity and tumor-selective recognition. This platform is particularly impactful for developing therapeutic vaccines against epithelial malignancies, including breast, colorectal, pancreatic, and ovarian cancers.

Carbohydrate-focused vaccine development employs well-characterized glycans—either biologically purified or chemically synthesized—as antigenic scaffolds. Derived from tumor or microbial surfaces (e.g., Globo H, Lewis antigens, sialyl-Tn), these carbohydrate moieties are conjugated to carrier proteins to surmount their inherent immunogenic limitations. When combined with appropriately matched adjuvants, these glycan-protein conjugates elicit robust, antigen-specific immune responses.

Creative Biolabs supports the full spectrum of antigen development, from rational design and chemical synthesis/isolation of glycan structures to carrier conjugation via advanced linker chemistries and multivalent construct formulation. This versatile approach caters to both anti-cancer and anti-bacterial vaccine modalities, offering a targeted strategy to engage conserved glyco-epitopes with minimal cross-reactivity. Backed by robust glycan characterization methodologies, our service is tailored to meet the needs of clients advancing carbohydrate-based therapeutics through preclinical and translational stages.